CVE:VPT VentriPoint Diagnostics (VPT) Stock Price, News & Analysis C$0.18 +0.01 (+2.86%) (As of 09/6/2024 05:28 PM ET) Add Compare Share Share Today's RangeC$0.18▼C$0.1850-Day RangeC$0.18▼C$0.2252-Week RangeC$0.14▼C$0.36Volume6,000 shsAverage Volume88,742 shsMarket CapitalizationC$28.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesInsider TradesStock AnalysisChartHeadlinesInsider Trades Get VentriPoint Diagnostics alerts: Email Address Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About VentriPoint Diagnostics Stock (CVE:VPT)Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients. Ventripoint Diagnostics Ltd. is headquartered in Toronto, Canada.Read More VPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VPT Stock News HeadlinesSeptember 3, 2024 | nz.finance.yahoo.comVentripoint Diagnostics Ltd. (VPT.V)August 21, 2024 | stockhouse.comVentripoint Receives Medical Device License from Health Canada to Sell Next Generation, AI-powered, Heart-scanning TechnologySeptember 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 6, 2024 | theglobeandmail.comVentriPoint Diagnostics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (VPT)May 24, 2024 | theglobeandmail.comClosing Bell: Ventripoint Diagnostics Ltd up on Thursday (VPT)May 6, 2024 | finance.yahoo.comVentripoint's Next Generation, AI-powered Heart-scanning Technology Submitted to U.S Food and Drug AdministrationMay 6, 2024 | msn.comWill Shares Rise on Milestone Development for AI-Powered Heart Technology?May 6, 2024 | bbc.co.ukApproval for new NHS diagnostic centre in MansfieldSeptember 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.May 2, 2024 | finance.yahoo.comVentripoint Diagnostics Full Year 2023 Earnings: CA$0.031 loss per share (vs CA$0.031 loss in FY 2022)April 14, 2024 | morningstar.comVentriPoint Diagnostics Ltd VPTMarch 28, 2024 | finance.yahoo.comVentripoint Diagnostics Provides Corporate Update and Announces Conference CallMarch 4, 2024 | stockhouse.comEnhanced Design Breakthrough Makes Ventripoint's VMS+ Even Simpler to UseFebruary 21, 2024 | benzinga.comVentriPoint Diagnostics Stock (OTC:VPTDF) Dividends: History, Yield and DatesFebruary 14, 2024 | morningstar.comVentriPoint Diagnostics Ltd VPTDFFebruary 13, 2024 | stockhouse.comVentripoint Welcomes Bart Hendriks as New Strategic Partnerships Executive to Accelerate European and Global SalesFebruary 1, 2024 | es-us.finanzas.yahoo.comThe Medical University of Vienna's Paediatric Heart Centre Purchases Ventripoint's AI-Powered Heart Imaging SystemJanuary 29, 2024 | finance.yahoo.comThe 2023 Year in ReviewSee More Headlines Receive VPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VentriPoint Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolCVE:VPT CUSIPN/A CIKN/A Webwww.ventripoint.com Phone416-848-4156FaxN/AEmployees147,000Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-4,720,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-383.91% Return on Assets-103.52% Debt Debt-to-Equity Ratio217.41 Current Ratio0.42 Quick Ratio6.67 Sales & Book Value Annual SalesC$24,600.00 Price / Sales1,150.10 Cash FlowC$0.03 per share Price / Cash Flow5.53 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares157,180,000Free FloatN/AMarket CapC$28.29 million OptionableNot Optionable Beta0.43 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. George Adams B.A.Sc. (Age 76)ICD.D., M.A.Sc., Ph.D., Executive Chairman & Corporate Secretary Comp: $286kMr. Hugh MacNaughtInterim CEO, President & DirectorMr. Jimmy JeonChief Financial OfficerMr. Hirotaka KatagiriCTO & Business Development Division DirectorMatt DobsonMarketing DirectorMr. Jim GrabaApplication Specialist & Chief TrainerMr. Bart HendriksStrategic Partnership ExecutiveMore ExecutivesKey CompetitorsProtech Home MedicalCVE:PTQProtech Home MedicalCVE:PHMHelius Medical TechnologiesTSE:HSMTheralase TechnologiesCVE:TLTAurora SpineCVE:ASGView All CompetitorsInsidersHugh MacnaughtBought 20,000 shares on 5/2/2024Total: C$4,420.00 ($0.22/share)Robert HodgkinsonBought 4,500 shares on 4/26/2024Total: C$945.00 ($0.21/share)Robert HodgkinsonBought 21,000 shares on 4/24/2024Total: C$4,410.00 ($0.21/share)Robert HodgkinsonBought 75,000 shares on 4/22/2024Total: C$15,900.00 ($0.21/share)Robert HodgkinsonBought 36,500 shares on 4/18/2024Total: C$7,774.50 ($0.21/share)View All Insider Transactions VPT Stock Analysis - Frequently Asked Questions How have VPT shares performed this year? VentriPoint Diagnostics' stock was trading at C$0.30 on January 1st, 2024. Since then, VPT stock has decreased by 39.0% and is now trading at C$0.18. View the best growth stocks for 2024 here. How do I buy shares of VentriPoint Diagnostics? Shares of VPT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of VentriPoint Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VentriPoint Diagnostics investors own include Resverlogix (RVX), AuRico Gold Inc. Ordinary Share (AUQ), Kootenay Silver (KTN), ProMetic Life Sciences (PLI), Shopify (SHOP), Shockwave Medical (SWAV) and Barkerville Gold Mines Ltd. (BGM.V) (BGM). This page (CVE:VPT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VentriPoint Diagnostics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share VentriPoint Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.